About Dylan Sammut

Dylan joined Irving Levin in October 2018 as a Research and Editorial Associate and is responsible for reporting on mergers and acquisitions in the healthcare sector. He graduated from Alfred University in May 2014 with a degree in English and Political Science. He currently lives in Bridgeport, CT with his fiancé and his overweight cat, Kimba, and in his free time he plays video games, reads, writes, and hikes on the weekends all year around.

Articles Written by Dylan Sammut

Takeda Adds Maverick Therapeutics

Takeda Adds Maverick Therapeutics

The pharmaceutical giant Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) is back with a new acquisition. The company has announced the acquisition of Maverick Therapeutics, Inc for a pre-negotiated upfront payment as well as potential development and regulatory milestones... Read More »
WELL Health Builds Digital Health Portfolio

WELL Health Builds Digital Health Portfolio

The Canadian-based company WELL Health Technologies Corp. (TSX.V: WELL) went on an acquisition spree in 2020, adding a plethora of smaller, digital health companies to build up its product portfolio. Last week, they continued that spree, announcing the acquisition... Read More »
Amgen Acquires Five Prime Therapeutics

Amgen Acquires Five Prime Therapeutics

The biotech giant Amgen, Inc. (NASDAQ: AMGN) has announced a new deal for Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies. The company collaborates with leading global... Read More »
CROs Are Back in Demand

CROs Are Back in Demand

Last year was not kind to contract research organizations (CROs). CROs typically provide discovery and development services to companies in the Medical Device, Pharmaceutical and Biotechnology sectors, conducting clinical trials and providing a wealth of R&D... Read More »